Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: J02AX06

Ecalta(anidulafungin)

Candidiasis

Marketing Authorisation Holder: Pfizer Europe MA EEIG

EMA Authorisation: 20/09/2007

INN: anidulafungin

Indication

Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Ecalta — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.